CRISPR Therapeutics AG

CRSPintermediary

CRISPR Therapeutics made history with the first FDA-approved CRISPR gene-editing therapy, Casgevy, for sickle cell disease. Co-founded by Nobel laureate Emmanuelle Charpentier, the company is leveraging its gene-editing platform across hematology, oncology (allogeneic CAR-T), and in vivo applications to create potentially curative one-time treatments.

共有:

⇄ Compare

製品と売上

製品別売上シェア

売上内訳 ($0.4B)

静的データ（リアルタイム財務ロード中…）

Casgevy Product Revenue (50%)

Collaboration Revenue (Vertex) (35%)

Grants & Other (15%)

セグメント構成と主要顧客

製品詳細

Casgevy (Exagamglogene)50%

First CRISPR-based gene therapy approved for sickle cell disease and beta-thalassemia

CTX110 / Allogeneic CAR-T25%

Off-the-shelf CRISPR-edited CAR-T cell therapies for blood cancers

In Vivo Gene Editing25%

Next-gen lipid nanoparticle-delivered CRISPR for liver and other organs

サプライチェーン関係

競合他社

Regeneron Pharmaceuticals

Gene editing and genomic medicine

影響: Competing modalities

Moderna, Inc.

Gene therapy delivery platforms

影響: Competing therapeutic platforms

パートナー

Alnylam Pharmaceuticals, Inc.

Complementary genetic medicine approaches

影響: Potential future collaboration

マクロ・市場概況

제약 / 바이오セクターニュース

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

次の主要イベント

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI分析

CRISPR Therapeutics AGのAIサプライチェーン分析を受けるには「AI分析を取得」をクリックしてください。

企業情報

本社所在地

Zug, Switzerland

設立

2013

従業員数

1,400+

ウェブサイト

crisprtx.com

セクター概況 — 제약 / 바이오

セクターニュース